The antiarrhythmic medicine sales in Italy are projected to show moderate growth from 2024 to 2028. In 2024, sales start at $2.4 per capita, increasing to $2.5 in 2025, remaining steady in 2026, and then gradually rising to $2.6 by 2027 and continuing through 2028. The year-on-year growth is consistent yet modest, indicating roughly a 4.2% growth rate from 2024 to 2028 on average per annum (CAGR). As we are in 2024, the precise previous year data for 2023 is unavailable, yet these projections suggest a stable market outlook.
Trends to watch for include technological advancements in drug development, healthcare policy changes, and demographic shifts such as an aging population that could drive demand for antiarrhythmic medications. Additionally, ongoing research and development in personalized medicine may influence future sales patterns.
